GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

GSK Carlisle — GSK is phasing out production at its Carlisle, PA, production facility by mid-2021 and will full exit the site by the end of that year.

Approval in the US of the first OTC prescription-strength, nonsteroidal anti-inflammatory topical gel for arthritis isn’t GlaxoSmithKline PLC’s only recent consumer health development.

In addition to a green light for marketing Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) OTC, the UK pharma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Poland’s Formeds Acquired By Private Equity

05 Jun 2025

• By Tom Gallen

Enterprise Investors takes 77% stake in Polish clean-label dietary supplements manufacturer Formeds.

BioGaia Takes Probiotics To Netherlands For First Time

02 Jun 2025

• By Tom Gallen

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

Urgo Makes Moves In Poland And Belgium

29 May 2025

• By Tom Gallen

French consumer health player Urgo has added to its dietary supplements offering with separate deals in Poland and Belgium.

Dermapharm Seeks To Put Stop To Spanish Slide

23 May 2025

• By Tom Gallen

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

27 May 2025

• By David Ridley

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.